Establishment Labs Stock Looks Fair on Cash Flow, Rich on Sales

Establishment Labs looks improved, but the multiple still assumes more than one quarter proved

At issue now is when Establishment Labs earns its premium, not whether the business is improving. The market is pricing it like a broader platform today on a trailing P/S of 9.3x, even though the quarter delivered only the early signals bulls have been waiting for: Q2 revenue of US$67.5m, adjusted EBITDA of US$3.7m, and 70.6% gross margin. That is the split investors still need to resolve. Bulls believe the premium will be validated as the mix shifts and U.S. momentum compounds. Bears think a rich sales multiple leaves too little room for a slow buildout.

What the quarter showed

Q2 improved the story, but it did not settle it. Revenue rose meaningfully year over year, adjusted EBITDA turned positive, and management raised 2026 revenue guidance. That shows operating progress is real, not theoretical. But the stock is still being valued less like a company that is simply getting better and more like a company that has already moved from product strength into platform status.

The bull case has real evidence behind it. U.S. revenue reached US$24.7m, now 36.6% of sales, which makes America look less like a future option and more like a central growth driver. But the stock still sits between "good trajectory" and "proven platform." That is where investor psychology takes over: believers can treat each milestone as confirmation of a bigger winner, while skeptics can treat any pause as proof the thesis is still incomplete.

The key question is whether U.S. expansion and mix improvement can close that gap before expectations outrun execution.

The real debate is whether U.S. strength is enough to support platform-level valuation

The quarter did not settle the case. It made the disagreement clearer.

Why bulls are focused on the U.S. turn

Bulls are leaning on recent momentum, but it is more than a headline chase. U.S. revenue reached US$24.7m, up 140.9% year over year, and 36.6% of sales. At that scale, the U.S. stops looking like a future story and starts looking like the main operating engine.

The mix data also helps the case. Minimally invasive platform revenue reached US$12.1m, which gives bulls a second growth leg to anchor the platform thesis. The argument is not just about more revenue. It is about a better revenue mix: higher-value procedures, stronger surgeon training, and an anchor market that could pull overall economics upward faster than a traditional implant-only model.

Why bears still see a still-expensive niche business

Bears are focusing on how narrow the improvement still looks. OUS revenue grew only 4.4%, which suggests the company still lacks broad global penetration. If this were a fully proven platform, the rest of the business would not look quite so static.

The expense picture also keeps the debate alive. Operating expenses were US$52m in the quarter, against an adjusted EBITDA improvement of US$12.2m. Bears will argue that a thin move to profitability is not enough to justify a platform-style multiple on sales.

There is also no easy near-term shortcut in the roadmap. Reconstruction is under FDA review with no 2026 revenue expected, which means the next few quarters still have to prove the core model first.

What the November report needs to show

The next print should reveal which read is closer to reality:

• U.S. share keeps rising: the America mix should continue to expand, not stall after one strong quarter.
• Platform revenue keeps growing:minimally invasive platform revenue needs to deepen as a second growth leg.
• OUS improves: international revenue outside the U.S. cannot stay stuck at low-single-digit growth if the platform story is becoming real.
• Operating leverage holds: EBITDA should keep improving without expenses running ahead of the growth story.

Valuation now depends on repeatable execution, not just one strong quarter

The setup is less about debating valuation in the abstract and more about using the next earnings window to test whether the premium is being earned in real time. The next report lands on Nov. 10, and the calendar cuts both ways: Q3 is expected to be weaker due to seasonality, Q4 typically strongest. That makes November better for checking direction than for demanding perfection, while year-end looks like the more decisive proof point.

What would justify the premium

The stock does not need another good headline. It needs evidence that the recent operating turn is becoming repeatable across the business, not just concentrated in one geography or one quarter. A premium multiple gets validated when adoption starts to look structural: the U.S. engine keeps lifting the mix, the platform narrative broadens beyond the core product, and profitability improves without leaning too heavily on hope.

That is why the balance sheet matters. Cash and cash equivalents reached US$71.2m, which reduces dilution anxiety and gives management more time to execute. But time alone does not justify the multiple. It only preserves the window in which the market will keep waiting for proof.

What could force a reset

A reset does not require a collapse. It happens if the latest results suggest the recent progress was too narrow, too fragile, or too costly to sustain. If the company falls back on one standout market while the broader base stalls, the stock can move quickly from "early platform" to "overvalued growth story."

Watch these triggers over the next two quarters:

• U.S. share continuing to rise: the America mix should keep expanding, not reverse after this burst.
• Platform revenue expanding:minimally invasive platform revenue needs to deepen as a more meaningful second leg.
• Gross margin holding up:gross margin of 70.6% should remain supportive if the mix story is real.
• Profitability improving further:adjusted EBITDA turned positive at US$3.7m is a step forward, but one quarter is not enough on its own.
• Capital-allocation discipline:cash and cash equivalents reached US$71.2m should reduce pressure for future equity funding and support patient scaling.

ESTA is still a show-me stock, not a believe-me stock. The November 10 report should help confirm trajectory, while the stronger second-half build can help judges whether the premium multiple should expand, hold, or reset.